Results 51 to 60 of about 10,088 (191)
Background: Rifaximin is a non-aminoglycoside antibiotic utilized for the treatment of mastitis in cows, but its milk disposition kinetics, residue, and bacteriological status in lactating cow milk have hardly been reported.
Na Yu +6 more
doaj +1 more source
Repurposing antimicrobial agents for neuroprotection: Mechanisms, clinical potential, and challenges
Antimicrobial agents exert neuroprotective effects through modulation of interconnected pathways. Tetracyclines, macrolides, antimalarial agents, sulfones, and antiparasitic agents suppress neuroinflammation, oxidative stress, and apoptosis while preserving mitochondrial function and neurotransmission.
Mohammad Amin Manavi +5 more
wiley +1 more source
Gut Microbiota Modulation and Mucosal Immunity: Focus on Rifaximin
The gastrointestinal tract is a complex and dynamic network where an intricate and mutualistic symbiosis modulates the relationship between the host and the microbiota in order to establish and ensure gut homeostasis.
Lopetuso, Loris Riccardo +3 more
core +1 more source
Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy. [PDF]
Hepatic encephalopathy (HE) represents a dysfunctional gut-liver-brain axis in cirrhosis which can negatively impact outcomes. This altered gut-brain relationship has been treated using gut-selective antibiotics such as rifaximin, that improve cognitive ...
Jasmohan S Bajaj +15 more
doaj +1 more source
Recompensation of Cirrhosis: A New Treatment‐Related Disease State
This perspective article conceptualizes recompensation of cirrhosis as a distinct treatment‐related disease state rather than mere transient clinical improvement after etiology‐directed therapy, and further proposes a four‐state classification including compensated cirrhosis, stable recompensation, unstable recompensation, and persistent decompensation
Wentao Tan +5 more
wiley +1 more source
Rifaximin Exerts Beneficial Effects Independent of its Ability to Alter Microbiota Composition [PDF]
Rifaximin has clinical benefits in minimal hepatic encephalopathy (MHE) but the mechanism of action is unclear. The antibiotic-dependent and -independent effects of rifaximin need to be elucidated in the setting of MHE-associated microbiota.
Kakiyama, Genta +21 more
core +1 more source
Novel therapeutic targets for chronic visceral pain in gastrointestinal disorders
Chronic visceral pain imposes a major clinical challenge in gastroenterology and beyond, profoundly impacting patients' quality of life. However, limited understanding of its complex, multifaceted pathophysiology, encompassing both peripheral and central mechanisms, continues to impede the development of effective management strategies.
Fleur Veldman +3 more
wiley +1 more source
Background and Purpose Modifying the brain–gut–microbiota axis has emerged as a promising therapeutic strategy against Alzheimer's disease (AD). Whether rifaximin, a non‐absorbed and non‐systemic antibiotic, can be applied to the treatment of AD remains unexplored.
Di Wu +7 more
wiley +1 more source
In a recent article, Longman and Swaminath analyzed our paper on the use of rifaximin in patients with moderately active Crohn's disease (CD). Here we report some considerations concerning their article. The exploratory post-hoc subgroup analysis showed that early-stage disease and, differently from that written by Longman and Swaminath, also colonic ...
Cosimo, Prantera, Maria Lia, Scribano
openaire +2 more sources
Effect of Rifaximin on Hepatic Fibrosis in Bile Duct-ligated Rat Model
Background/Aims: The translocation of bacteria and their lipopolysaccharides from the gut can promote fibrosis in cirrhotic patients. The aim of this study was to investigate the effects of rifaximin on hepatic fibrosis in a bile duct-ligated rat model ...
Seung Kak Shin +8 more
doaj +1 more source

